Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...

Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi, or lisocabtagene maraleucel, in adult patients with ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits ...

The live birth rate was lower for women with low odds for IVF success when all embryos were frozen and transferred later than ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Cannabidiol may reduce scan-related anxiety among women with advanced breast cancer, according to results of randomized phase ...

CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b ...

NEW TAIPEI CITY, Taiwan I February 9, 2025 I Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE).

An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.